The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.

The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.